Ultragenyx Pharmaceutical Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript

Jan 13, 2022 / 12:00PM GMT
Xiaodong Zhang - H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst

Hello, everyone. I'm Edwin Zhang a biotech analyst here at H.C. Wainwright. Welcome to our 2022 BioConnect Conference. It's my great pleasure to introduce Dr. Emil Kakkis, President and CEO of Ultragenyx. Welcome, Emil. Thanks for joining us.

Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks for having me, Edwin.

Xiaodong Zhang - H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst

Maybe first, Emil, could you give us a quick overview about the company and then we will dive into the clinical programs.

Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Sure. Ultragenyx is a rare disease company now entering our 12th year since founding. And we have, in that time, gone to 4 approvals for 3 products and are global rare disease company. We have 6 programs in the clinic, including

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot